Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1987; 57(03): 361-371DOI: 10.1055/s-0038-1651134 International Committee Communications Schattauer GmbH Stuttgart ICTH - Subcommittee on Clinical Trials: Registry of Multicenter Clinical Trials: Eighth Report - 1986 J P Boissel The Unité de Pharmacologie Clinique, Hôpital Neuro-Cardiologique, Lyon, France› Author AffiliationsRecommend Article Abstract PDF Download Buy Article PDF (1587 kb) References References 1 Verstraete M. Registry of prospective clinical trials. First report. Thrombos Diathes Haemorrh 1975; 33: 655-663 2 Verstraete M. Registry of prospective clinical trials. Second report. Thromb Haemostas 1976; 36: 239-250 3 Verstraete M. Registry of prospective clinical trials. Third report. Thromb Haemostas 1978; 39: 759-767 4 Verstraete M. Registry of prospective clinical trials. Fourth report. Thromb Haemostas 1980; 43: 176-181 5 Verstraete M. Registry of prospective clinical trials. Fifth report. Thromb Haemostas 1982; 48: 334-338 6 Verstraete M. Registry of prospective clinical trials. Sixth report. Thromb Haemostas 1984; 51: 283-290 7 Boissel J-P. Registry of prospective clinical trials. Seventh report. Thromb Haemostas 1986; 55: 282-291 8 GISSI Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1985; I: 397-401 9 ISAM Study Group Prospective placebo-controlled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): results on 21-day-mortality, morbidity and infarct size. NEJM 1986; 314: 1465-1471 10 Gold HK, Leinbach RC, Garabedian HD, Yasuda T, Johns JA, Grossbach EB, Palacios I, Collen D. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 1986; 73: 347-352 11 Simoons ML, Serruys PW, v/d Brand M, Bär F, de Zwaan C, Res J, Verheugt F WA, Krauss XH, Remme WJ, Vermeer F, Lubsen J. Improved survival after early thrombolysis in acute myocardial infarction; a randomised trial by the Interuniversity Cardiology Institute in the Netherlands. Lancet 1985; III: 578-581 12 Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. NEJM 1983; 309: 396-403 13 Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, Sackett DL, Sealey BJ, Tanser PH. Aspirin, sulfinpyrazone, or both in unstable angina. NEJM 1985; 313: 1369-1375 14 Kakkar VV, Murray W JG. Efficacy and safety of low-molecular-weight heparin (CY 216) in preventing post-operative venous thromboembolism: a cooperative study. Br J Surg 1985; 72: 786-791 15 Turpie A GG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. NEJM 1986; 315: 925-929 16 De Feudis FV. “Calcium-antagonists” and atherosclerosis; basic studies and therapeutic implications. Life Sciences 1983; 32: 557-563
